Cue Biopharma is an innovative clinical stage immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system. Our Immuno-STAT (Selective Targeting and Alteration of T Cells) platform is designed to directly engage with and modulate the activity of antigen specific T cells in a patientâs body through a singular molecular framework. In addition to the selective control of T cell activity, we believe Immuno-STATs offer several key points of potential differentiation over competing approaches, including broad disease coverage, manufacturability, and convenient administration.
Source
